Healthcare consumerism and direct-to-consumer healthcare access Report Interpretation

Overview

Morgan Stanley presents healthcare consumerism as a structural shift from passive use of care toward greater patient choice, transparency, financial participation and direct access. The report links this transition to opportunities across managed care, pharmacies, diagnostics, distribution, telehealth and selected branded biopharma DTC channels.

Core views

Morgan Stanley argues that healthcare consumerism is broader than cash-pay spending: it is the growing ownership of the healthcare journey through choice of benefits and providers, visibility on prices, digital access, health-data control and more direct initiation of care. Policy changes, high-deductible plans, HSAs, price-transparency rules, patient-data access, telehealth, wearables and digital platforms have progressively shifted financial and informational control toward patients. The report expects models emphasizing transparency and choice to take a larger role in the U.S. healthcare ecosystem, while noting limits on out-of-pocket spending, macro sensitivity and other risk factors. The report’s August 2026 AlphaWise survey supports the demand side of this thesis. Twenty-five percent of consumers said they had paid fully out of pocket for at least one healthcare service in the prior year, led by behavioral and mental-health services at 8% and medical weight management at 6%; 36% said they would be willing to pay fully out of pocket for services. Thirty-one percent reported fully out-of-pocket spending on at least one medication or treatment, and 38% said they would pay for an ongoing health condition. Across all consumers, estimated annual out-of-pocket spending on healthcare services and medicines was about $908, compared with stated maximum willingness to spend of about $2,043. The willingness and usage measures skew higher among younger and higher-income cohorts. Within healthcare services, Morgan Stanley sees vertically integrated managed-care companies as best placed to benefit because they operate across benefits, care navigation, routine and virtual care, pharmacy, chronic-condition management, home-based care and consumer data. It identifies UnitedHealth Group, CVS Health and Cigna as particularly advantaged by their combinations of payer relationships, provider access, pharmacy capabilities, digital tools and incentives to steer members toward suitable lower-cost settings. The report argues that these multiple touchpoints allow such companies to simplify an otherwise fragmented journey while coordinating outcomes and costs. The report views DTC pharmacy as an additional access layer rather than a replacement for insurance, PBMs or traditional distribution. Digital pharmacies improve convenience; transparent pharmacies emphasize upfront cash pricing; telehealth and subscription platforms combine virtual care, prescribing and fulfillment; and manufacturer-led platforms seek a direct relationship with patients. Traditional retail pharmacies remain the dominant fulfillment route, however. In the May 2026 survey, CVS accounted for 23% of prescription-delivery use over the prior year, Walmart for 16% and Walgreens for 15%, while Amazon Pharmacy gained approximately 2 percentage points year over year. The report expects traditional pharmacies to respond through digital prescription management, delivery, price tools, more transparent reimbursement and expanded care offerings. For biopharma, Morgan Stanley argues that GLP-1 obesity therapies demonstrated that branded prescription drugs can sustain material consumer-led access when demand exceeds available reimbursement. Lilly reported self-pay represented roughly 45% of total Zepbound prescriptions and roughly 55% of new prescriptions in 2Q26; the report also cites DTC channels representing more than 50% of weekly Zepbound prescriptions in the week ended June 26. It characterizes the relevant opportunity as a parallel access infrastructure in which patients can discover a product, see a price, obtain a digital prescription and fill through a manufacturer-selected pharmacy or partner. Morgan Stanley applies a four-gate screen to determine whether a drug can support DTC cash-pay demand: self-administration, clinical suitability for a telehealth-originated pathway, viable cash-pay economics and absence of prohibitive legal or regulatory barriers. The screen excludes many infused therapies, oncology, cell and gene therapy, products requiring complex diagnostics, and therapies constrained by REMS or certain controlled-substance rules. Applying the screen to its biopharma coverage produces a bottom-up peak-U.S. DTC TAM of approximately $26 billion, with $15 billion and $41 billion bear and bull cases using 0.6x and 1.6x multipliers on modeled DTC shares. The base case is roughly 5% of branded retail spend and roughly 3% of total branded pharmaceutical spend. Obesity is the largest modeled DTC category at $11.8 billion, or 46% of TAM, and 43% of obesity TAM is pipeline-related. Pipeline assets represent 31% of total modeled TAM, making launches an important dependency. The report emphasizes that therapy persistence is the key durability variable: a patient who lapses after four months is much less valuable than one who remains on therapy for a year. It also states that DTC share is inversely related to reimbursement progress; expanding employer GLP-1 coverage toward approximately 60-65% could narrow the cash-pay share even as the overall revenue pool grows. Morgan Stanley is selective about the TrumpRx and manufacturer-DTC theme. TrumpRx is described as a federally operated price-discovery and pharmacy-routing layer, not a pharmacy that prescribes, dispenses or fulfills prescriptions. Of 93 branded TrumpRx listings, 30 route to a manufacturer-owned storefront and 63 redeem as retail coupons. The report argues that headline discounts are not sufficient evidence of attractive economics: across 29 same-molecule branded and generic pairs, 19 branded listings were more expensive than generics at a median 4.7x premium. The institution therefore focuses on on-patent products with real consumer demand, persistent reimbursement friction, viable cash pricing and an owned consumer channel rather than treating all DTC or TrumpRx participation as equivalent. The report also identifies adjacent opportunities. Consumer diagnostics is estimated as a $4 billion U.S. market that has more than doubled since 2021; Quest’s consumer platform reached approximately $250 million of revenue and was growing about 30% year over year in 2026. Morgan Stanley is bullish on consumer-driven testing and estimates preventative testing, screening and monitoring could avoid roughly $200-800 billion of preventable-disease gross spend by 2050E. It also expects drug distributors to remain insulated because DTC pharmacies still rely on conventional distribution infrastructure.

Analysis framework

Morgan Stanley combines consumer surveys, transaction and web-traffic indicators, company disclosures, industry data and case studies. It maps healthcare companies across the consumer journey, assesses DTC platform models, and uses a four-gate drug screen plus peak-sales estimates, access assumptions and scenario multipliers to construct a bottom-up DTC therapeutic TAM.

Methodology notes

• Industry AnalysisUpstream-Midstream-Downstream Transmission

  Healthcare consumer-journey and access-channel mapping

  The report maps how payers, providers, pharmacies, distributors, technology platforms and manufacturers participate at different stages of the consumer journey and how consumer choice affects each layer.

• Other

  Four-gate DTC screener and bottom-up DTC TAM model

  The report screens therapies for self-administration, clinical fit, cash-pay economics and legal barriers, then applies modeled DTC shares to peak U.S. sales estimates to size the opportunity.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• UnitedHealth Group (UNH)

  Overweight managed-care company positioned across benefits, navigation, care delivery, pharmacy and consumer data.

  Strengths

  UnitedHealthcare and Optum provide multiple member touchpoints, personalized navigation, care delivery, pharmacy services and home-based care.

  Comparison

  Morgan Stanley groups UNH with CVS and Cigna as the best-positioned vertically integrated managed-care companies.

• CVS Health (CVS)

  Overweight integrated payer, pharmacy and care-delivery platform.

  Strengths

  Aetna, Caremark, CVS Pharmacy, MinuteClinic, Oak Street and Signify provide broad consumer access points.

  Weaknesses

  Traditional pharmacy operations face consumer-demand, footprint and pricing pressures.

  Comparison

  Highlighted alongside UNH and Cigna for broad coverage of the consumer journey.

• Cigna (CI)

  Overweight managed-care company with benefit, digital-navigation and Evernorth pharmacy capabilities.

  Strengths

  myCigna, Express Scripts, Accredo, MDLIVE and care-management capabilities support navigation and medication access.

  Comparison

  Highlighted alongside UNH and CVS as best positioned in consumerism.

• Hims & Hers Health (HIMS)

  Equal-weight DTC telehealth platform and a leading scaled consumer-health example.

  Strengths

  Subscriber growth, expanding categories, technology investment and potential evolution toward preventive care.

  Weaknesses

  Investment cycle, slowing ED growth and a shift toward branded GLP-1 offerings are weighing on margins.

  Comparison

  Larger, better-capitalized DTC platforms are viewed as advantaged over smaller niche platforms.

  Risks

  2026 EBITDA margin guidance of 9.4% is down 410 basis points year over year; estimated gross margin is expected to decline 960 basis points to 64.2%.

• GoodRx (GDRX)

  Equal-weight consumer-access platform shifting toward subscriptions and Pharma Direct.

  Strengths

  Price transparency, virtual care, manufacturer programs and asset-light links across consumers, pharmacies and manufacturers.

  Weaknesses

  Legacy prescription-business weakness has offset growth in Pharma Direct.

  Comparison

  Unlike vertically integrated telehealth platforms, GoodRx operates as an asset-light layer across healthcare participants.

  Risks

  Re-rating depends on stabilization of the core prescriptions business, Pharma Direct scaling and subscription execution.

• Quest Diagnostics (DGX)

  Overweight clinical laboratory positioned for consumer-driven testing.

  Strengths

  QuestHealth.com, partnerships and a consumer platform at approximately $250 million of revenue growing about 30% year over year in 2026.

  Comparison

  Viewed with Labcorp as well positioned for preventative and voluntary testing.

Key data

• Peak U.S. DTC therapeutic TAM~$26 billionMorgan Stanley base case for screened branded cash-pay therapeutics; $15 billion bear case and $41 billion bull case.
• Obesity share of DTC TAM46%Equivalent to $11.8 billion of modeled TAM; 43% of obesity TAM is pipeline-related.
• Consumers paying fully OOP for healthcare services25%AlphaWise August 2026 survey, prior 12 months.
• Consumers willing to pay fully OOP for healthcare services36%Skews toward younger and higher-income consumers.
• Annual healthcare OOP spend versus maximum willingness~$908 versus ~$2,043Estimated average across all surveyed consumers for services and medications.
• Zepbound self-pay share~45% of total prescriptions; ~55% of new prescriptionsReported by Lilly for 2Q26, according to the report.
• TrumpRx manufacturer-owned storefront routing30 of 93 branded listingsThe remaining 63 listings redeem as retail coupons.
• Cash payer cost per branded prescription$254 versus $27 for commercially insured patientsApproximately 9x higher; the gap has doubled since 2020.

Impact & implications

The report sees healthcare consumerism as an opportunity for businesses that can combine choice, navigation, access, affordability, fulfillment and data across the patient journey. It favors vertically integrated managed-care companies within coverage, views DTC biopharma opportunity as concentrated rather than universal, and considers consumer diagnostics and distribution infrastructure additional beneficiaries of the shift.

Risks

• Cash-paid therapy persistence is the key durability risk for the modeled DTC opportunity.
• Broader employer and payer coverage, particularly for obesity therapies, could compress cash-pay demand.
• Pipeline assets account for 31% of modeled DTC TAM, making the opportunity partly dependent on future launches.
• DTC models are constrained where therapies require in-person infrastructure, specialist diagnostics, REMS compliance or restrictive controlled-substance rules.
• Consumer healthcare adoption remains subject to macro sensitivity and limits on out-of-pocket spending.

What to watch

• The pace of employer GLP-1 coverage expansion toward the report’s approximately 60-65% assumption.
• Cash-pay persistence and repeat economics for DTC therapies.
• Whether MRK’s Lipfendra demonstrates that DTC can extend beyond obesity into chronic primary-care markets.
• Execution and margin recovery at Hims & Hers as it expands products, technology and international operations.
• Stabilization in GoodRx’s core prescriptions business and scaling of Pharma Direct and subscriptions.
• The extent to which manufacturers build owned consumer channels rather than relying on retail coupon redemption.